Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; a research collaboration partnership with the University of California San Diego to develop off-the-shelf chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. It also has a strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
It is on my watch list now. Not sure how or why it got there. It's long list. I grab stuff from everywhere.
Cathie Wood's ARK Invests Posts Fund Purchases For Wednesday, Feb. 3, 2021: NVS, VRTX, SPOT, PCAR, FATE, TER 8:44 pm ET February 3, 2021 (Benzinga) Print Novartis (NVS) - 299,907 Shares Vertex Pharmaceuticals (VRTX) - 57,100 Spotify Technology (SPOT) - 503,728 Paccar (PCAR) - 318,474 Fate Therapeutics (FATE) - 98,059 Teradyne (TER) - 294,043 © 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
yes, @rg7803 , it is curious that a drug company that produces immunotherapies for cancer would call itself fate. your destiny could go either way, but all a matter of fate. and, yes, nice head and shoulders.
she's buying more, ladies and germs. your ride is here. get on board and buckle up. see you at the top. Cathie Wood's ARK Invest Posts Fund Purchases For Wednesday, Feb. 17, 2021: ABBV, VEEV, SGFY, EXAS, CMLF, BFLY, TSLA, SHOP, NTDOY, IRDM, FATE, BEAM, TDY, RAVN, KMTUY 7:02 pm ET February 17, 2021 (Benzinga) Print Abbvie (ABBV) - 294,600 Shares Veeva Systems (VEEV) - 46,198 Signify Health (SGFY) - 228,881 Exact Sciences (EXAS) - 651,658 CM Life Sciences (CMLF) - 228,824 Butterfly Network (BFLY) - 145,660 Tesla (TSLA) - 132,128 Shopify (SHOP) - 52,281 Nintendo (NTDOY) - 69,200 Iridium Communications (IRDM) - 184,000 Fate Therapeutics (FATE) - 79,517 Beam Therapeutics (BEAM) - 71,530 Teledyne Technologies (TDY) - 519 Raven Industries (RAVN) - 14,414 Komatsu (KMTUY) - 19,200 © 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
your mom and i got you some nice long green candles for your cake. be a good little boy and don't blow them out too quickly and smear wax all over the cake.
